Legend Biotech (LEGN) drew fresh investor attention after announcing that interim CEO Alan Bash will speak at the Morgan Stanley Global Healthcare Conference on September 15, 2026. The company plans to highlight its CAR-T focus and commercial footprint during the event.
Legend Biotech’s share price has been volatile, with a 13.91% 1 month share price return, followed by a 41.27% decline over 3 months and a 38.25% fall in 1 year total shareholder return. This suggests that long term momentum has been fading even as interest around events like this conference appearance picks up again in the short term.
Scan beyond Legend Biotech and compare how other healthcare stocks are priced for potential rebounds using our hand picked 50 high quality undervalued stocks.
For Legend Biotech, the question now is whether the sharp swing in returns reflects investors reassessing its CAR-T business, or simply a reset in sentiment around a volatile stock as the next leg of valuation work begins.
Most Popular Narrative: 57.1% Undervalued
Legend Biotech’s most followed narrative pegs fair value at $49.25 against a last close of $21.13, which frames the recent volatility against a sizeable valuation gap.
Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and -6), and label updates that increase patient access, setting up long-term revenue acceleration as the patient pool widens.
Want to see what sits behind that growth path for Legend Biotech? The narrative leans on rising revenue, higher margins, and a richer earnings profile. Curious which specific building blocks support that fair value and how they tie into future profitability.
Result: Fair Value of $49.25 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, Legend Biotech still faces meaningful risks, including reliance on CARVYKTI for revenue, as well as the potential impact of leadership changes on execution and partnerships.
Find out about the key risks to this Legend Biotech narrative.
Next Steps
Does the mix of risks and rewards around Legend Biotech leave you confident or cautious? Act while sentiment is in flux and form your own judgment by reviewing the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond Legend Biotech?
If Legend Biotech has sharpened your focus, now is the moment to broaden your watchlist and line up your next investment moves with help from targeted screeners.
Leave a comment